Abbott Laboratories Receivables 2010-2025 | ABT
Abbott Laboratories receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
- Abbott Laboratories receivables for the quarter ending March 31, 2025 were $6.925B, a 5.48% increase year-over-year.
- Abbott Laboratories receivables for 2024 were $6.925B, a 5.48% increase from 2023.
- Abbott Laboratories receivables for 2023 were $6.565B, a 5.58% increase from 2022.
- Abbott Laboratories receivables for 2022 were $6.218B, a 4.15% decline from 2021.
| Abbott Laboratories Annual Receivables (Millions of US $) |
|
|---|---|
| 2024 | $6,925 |
| 2023 | $6,565 |
| 2022 | $6,218 |
| 2021 | $6,487 |
| 2020 | $6,414 |
| 2019 | $5,425 |
| 2018 | $5,182 |
| 2017 | $5,249 |
| 2016 | $3,248 |
| 2015 | $3,418 |
| 2014 | $3,586 |
| 2013 | $3,986 |
| 2012 | $7,613 |
| 2011 | $7,684 |
| 2010 | $7,184 |
| 2009 | $6,542 |
| Abbott Laboratories Quarterly Receivables (Millions of US $) |
|
|---|---|
| 2024-12-31 | $6,925 |
| 2024-09-30 | $7,051 |
| 2024-06-30 | $6,854 |
| 2024-03-31 | $6,605 |
| 2023-12-31 | $6,565 |
| 2023-09-30 | $6,499 |
| 2023-06-30 | $6,172 |
| 2023-03-31 | $6,020 |
| 2022-12-31 | $6,218 |
| 2022-09-30 | $6,408 |
| 2022-06-30 | $7,199 |
| 2022-03-31 | $7,179 |
| 2021-12-31 | $6,487 |
| 2021-09-30 | $6,405 |
| 2021-06-30 | $6,113 |
| 2021-03-31 | $6,096 |
| 2020-12-31 | $6,414 |
| 2020-09-30 | $5,649 |
| 2020-06-30 | $5,140 |
| 2020-03-31 | $5,292 |
| 2019-12-31 | $5,425 |
| 2019-09-30 | $5,450 |
| 2019-06-30 | $5,548 |
| 2019-03-31 | $5,345 |
| 2018-12-31 | $5,182 |
| 2018-09-30 | $5,271 |
| 2018-06-30 | $5,192 |
| 2018-03-31 | $5,356 |
| 2017-12-31 | $5,249 |
| 2017-09-30 | $4,800 |
| 2017-06-30 | $4,633 |
| 2017-03-31 | $4,510 |
| 2016-12-31 | $3,248 |
| 2016-09-30 | $3,320 |
| 2016-06-30 | $3,567 |
| 2016-03-31 | $3,430 |
| 2015-12-31 | $3,418 |
| 2015-09-30 | $3,460 |
| 2015-06-30 | $3,553 |
| 2015-03-31 | $3,481 |
| 2014-12-31 | $3,586 |
| 2014-09-30 | $3,618 |
| 2014-06-30 | $4,056 |
| 2014-03-31 | $3,883 |
| 2013-12-31 | $3,986 |
| 2013-09-30 | $3,883 |
| 2013-06-30 | $3,939 |
| 2013-03-31 | $3,918 |
| 2012-12-31 | $7,613 |
| 2012-09-30 | $6,949 |
| 2012-06-30 | $6,768 |
| 2012-03-31 | $7,660 |
| 2011-12-31 | $7,684 |
| 2011-09-30 | $7,044 |
| 2011-06-30 | $7,038 |
| 2011-03-31 | $7,160 |
| 2010-12-31 | $7,184 |
| 2010-09-30 | $6,249 |
| 2010-06-30 | $6,338 |
| 2010-03-31 | $6,520 |
| 2009-12-31 | $6,542 |
| 2009-09-30 | $5,475 |
| 2009-06-30 | $5,453 |
| 2009-03-31 | $5,227 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $231.816B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $152.176B | 38.10 |
| Stryker (SYK) | United States | $145.393B | 30.40 |
| EssilorLuxottica (ESLOY) | France | $127.544B | 0.00 |
| Medtronic (MDT) | Ireland | $107.067B | 15.63 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.941B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.416B | 27.54 |
| ResMed (RMD) | United States | $35.930B | 26.99 |
| GE HealthCare Technologies (GEHC) | United States | $31.992B | 15.19 |
| Agilent Technologies (A) | United States | $30.486B | 20.14 |
| Terumo (TRUMY) | Japan | $28.205B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $23.066B | 16.58 |
| Insulet (PODD) | United States | $21.859B | 85.82 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.837B | 12.10 |
| Baxter (BAX) | United States | $15.857B | 11.84 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.412B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.030B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.686B | 22.60 |
| Lantheus Holdings (LNTH) | United States | $5.655B | 14.27 |
| Prestige Consumer Healthcare (PBH) | United States | $4.325B | 19.27 |
| Perrigo (PRGO) | Ireland | $3.713B | 9.41 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.426B | 14.92 |
| ICU Medical (ICUI) | United States | $3.404B | 25.10 |
| Envista Holdings (NVST) | United States | $2.981B | 24.77 |
| QuidelOrtho (QDEL) | United States | $2.458B | 16.90 |
| GN Store Nord (GNNDY) | Denmark | $2.075B | 17.18 |
| LeMaitre Vascular (LMAT) | United States | $1.813B | 40.53 |
| AtriCure (ATRC) | United States | $1.534B | 0.00 |
| Neogen (NEOG) | United States | $1.296B | 16.58 |
| Green Thumb Industries (GTBIF) | United States | $1.173B | 26.38 |
| Kestra Medical Technologies (KMTS) | United States | $1.164B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.156B | 11.75 |
| BioLife Solutions (BLFS) | United States | $1.106B | 0.00 |
| InMode (INMD) | Israel | $1.005B | 9.20 |
| Phibro Animal Health (PAHC) | United States | $0.910B | 11.64 |
| Evolus (EOLS) | United States | $0.632B | 0.00 |
| CeriBell (CBLL) | United States | $0.577B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.557B | 0.00 |
| Owens & Minor (OMI) | United States | $0.542B | 4.49 |
| Valneva SE (VALN) | France | $0.541B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.504B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.431B | 0.00 |
| Surmodics (SRDX) | United States | $0.383B | 0.00 |
| Omeros (OMER) | United States | $0.360B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.358B | 0.00 |
| SNDL (SNDL) | Canada | $0.339B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.290B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.288B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.283B | 10.42 |
| Aurora Cannabis (ACB) | Canada | $0.273B | 48.50 |
| Sanuwave Health (SNWV) | United States | $0.258B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.250B | 21.07 |
| Verano Holdings (VRNOF) | United States | $0.248B | 0.00 |
| Cerus (CERS) | United States | $0.247B | 0.00 |
| ZimVie (ZIMV) | United States | $0.244B | 11.09 |
| Canopy Growth (CGC) | Canada | $0.241B | 0.00 |
| Biote (BTMD) | United States | $0.219B | 6.15 |
| Quanterix (QTRX) | United States | $0.205B | 0.00 |
| High Tide (HITI) | Canada | $0.194B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.176B | 14.18 |
| Brainsway (BWAY) | Israel | $0.164B | 51.24 |
| TriSalus Life Sciences (TLSI) | United States | $0.162B | 0.00 |
| Organigram Global (OGI) | Canada | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.147B | 18.16 |
| Jin Medical (ZJYL) | China | $0.130B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.110B | 0.00 |
| Exagen (XGN) | United States | $0.103B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.094B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
| MacroGenics (MGNX) | United States | $0.090B | 0.00 |
| Agape ATP (ATPC) | $0.078B | 0.00 | |
| Fonar (FONR) | United States | $0.077B | 10.77 |
| Veru (VERU) | United States | $0.074B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.063B | 0.00 |
| United Health Products (UEEC) | United States | $0.059B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.055B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Apyx Medical (APYX) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 56.00 |
| United-Guardian (UG) | United States | $0.037B | 12.79 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| Nephros (NEPH) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |